CD80 variant immunomodulatory proteins and uses thereof
AssigneeAlpine Immune Sciences, Inc.
InventorsRyan Swanson, Michael Kornacker
Life of this patent
Estimating the term…
Abstract
Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
Claims33
A purified CD80-Fc immunomodulatory protein consisting of a variant CD80 polypeptide, an Fc domain and a linker, wherein the variant CD80 polypeptide is linked to the Fc domain via the linker, and wherein:
- the variant CD80 polypeptide comprises a sequence of amino acids that exhibits at least 90% sequence identity to an unmodified CD80 polypeptide set forth in SEQ ID NO:
- 28, or a portion of SEQ ID NO:28 comprising an IgV domain, wherein the IgV domain is amino acids 35-135, 35-138, 37-138 or 35-141 of SEQ ID NO:1;
- and
- the variant CD80 polypeptide comprises the amino acid substitution V68M.
A purified CD80-Fc immunomodulatory protein comprising a variant CD80 polypeptide linked to an Fc domain, wherein:
- the variant CD80 polypeptide comprises a sequence of amino acids that exhibits at least 90% sequence identity to an unmodified CD80 polypeptide set forth in SEQ ID NO:
- 28, or a portion of SEQ ID NO:28 comprising an IgV domain, wherein the IgV domain is amino acids 35-135, 35-138, 37-138 or 35-141 of SEQ ID NO:1,
- the variant CD80 polypeptide comprises the amino acid substitution V68M;
- and
- the immunomodulatory protein does not comprise any additional IgSF domain.
Dependencies are inferred from the claim text.